Pharma News

Who are the leading innovators in embryonic stem cell culturing for the pharmaceutical industry?

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Embryonic stem cell culturing.

However, not all innovations are equal, and not all of them follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and transcription for AAV are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and knockin type transgenic animals are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and embryonic stem cell culturing, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Embryonic stem cell culturing is a key innovation area in pharmaceutical development

Embryonic stem cells are cells derived from the human embryo and, owing to its pluripotent characteristics, they have a wide range of therapeutic applications. Embryonic culture helps in cultivating an embryo under aseptic conditions on a nutrient medium. Embryonic culture is of two types, namely mature and immature embryo culture.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of embryonic stem cell culturing.

Key players in embryonic stem cell culturing – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Johnson and Johnson is one of the leading patent filers for embryonic stem cell culturing. The company is involved in developing several regenerative medicines and human embryonic stem cells. The company also entered into several agreements with other companies for the development of embryonic stem cells. It also established a committee on Advanced therapies to ensure standards are maintained during cell culturing.

In terms of application diversity, Bristol-Myers Squibb is the top company, followed by Shanghai LIDE Biotech and Vertex Pharmaceuticals. By means of geographic reach, Eisai holds the top position, while Bristol-Myers Squibb and Takeda Pharmaceutical are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Source link
#leading #innovators #embryonic #stem #cell #culturing #pharmaceutical #industry

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *